Targeted proteomics improves cardiovascular risk prediction in secondary prevention: the impact of statin treatment?

Eur Heart J. 2022 Oct 11;43(38):3811. doi: 10.1093/eurheartj/ehac329.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Cardiovascular Diseases* / prevention & control
  • Heart Disease Risk Factors
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Primary Prevention
  • Proteomics
  • Risk Factors
  • Secondary Prevention

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors